Literature DB >> 20187016

Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

Alon Vaisman1, Steven Orlov, Jonathan Yip, Cindy Hu, Terence Lim, Mark Dowar, Jeremy L Freeman, Paul G Walfish.   

Abstract

BACKGROUND: We present our ongoing experience in the use of postsurgical stimulated serum thyroglobulin (Stim-Tg) to assist in radioiodine remnant ablation (RRA) decision-making.
METHODS: Patients with low-risk well-differentiated thyroid carcinoma (WDTC) with undetectable anti-Tg antibodies were prospectively followed after total thyroidectomy and therapeutic central compartment neck dissection, when indicated.Stim-Tg was performed 3 months postoperatively and used to base RRA selection.
RESULTS: Of 104 patients, 59 patients (56.7%) had an undetectable Stim-Tg after thyroidectomy, 35 (33.7%) had Stim-Tg values of 1-5 microg/L, and 10 (9.6%) had Stim-Tg values >5 microg/L. RRA was administered to 1 patient (1.7%) with undetectable Stim-Tg, 6 patients (17.1%) with Stim-Tg1-5 microg/L, and 9 patients (90%) with Stim-Tg >5 microg/L, for a total of 16 patients (15.4%) receiving RRA. When compared to current RRA selection guidelines, the proposed protocol achieved a significantly lower RRA administration rate.
CONCLUSION: Stim-Tg measurement performed several months after total thyroidectomy is a useful objective parameter in assisting RRA decision-making for patients with low-risk WDTC. ( c) 2010 Wiley Periodicals, Inc. Head Neck, 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187016     DOI: 10.1002/hed.21371

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  19 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Managing newly diagnosed thyroid cancer.

Authors:  Anna M Sawka; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  CMAJ       Date:  2013-10-07       Impact factor: 8.262

3.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 5.  Treatment and follow-up of low-risk patients with thyroid cancer.

Authors:  Martin Schlumberger; Isabelle Borget; Camila Nascimento; Maryse Brassard; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

6.  Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Authors:  Steven Orlov; Farnaz Salari; Lawrence Kashat; Jeremy L Freeman; Allan Vescan; Ian J Witterick; Paul G Walfish
Journal:  Endocrine       Date:  2015-03-20       Impact factor: 3.633

7.  Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.

Authors:  Geum-Cheol Jeong; Minchul Song; Hee Jeong Park; Jung-Joon Min; Hee-Seung Bom; Sang-Geon Cho; Ki Seong Park; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Seong Young Kwon
Journal:  Nucl Med Mol Imaging       Date:  2016-05-13

Review 8.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.

Authors:  Andrew N Hoofnagle; Mara Y Roth
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

9.  Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.

Authors:  Lawrence Kashat; Steven Orlov; David Orlov; Jasmeet Assi; Farnaz Salari; Paul G Walfish
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

10.  Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.

Authors:  Pedro W Rosario; Thássio Leonardo Siman; Maria R Calsolari
Journal:  Endocrine       Date:  2014-09-11       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.